AR113771A1 - NUCLEIC ACID MOLECULE FOR THE REDUCTION OF PAPD5 AND PAPD7 mRNA IN THE TREATMENT OF HEPATITIS B INFECTION - Google Patents

NUCLEIC ACID MOLECULE FOR THE REDUCTION OF PAPD5 AND PAPD7 mRNA IN THE TREATMENT OF HEPATITIS B INFECTION

Info

Publication number
AR113771A1
AR113771A1 ARP180103000A ARP180103000A AR113771A1 AR 113771 A1 AR113771 A1 AR 113771A1 AR P180103000 A ARP180103000 A AR P180103000A AR P180103000 A ARP180103000 A AR P180103000A AR 113771 A1 AR113771 A1 AR 113771A1
Authority
AR
Argentina
Prior art keywords
papd5
nucleic acid
treatment
acid molecule
papd7
Prior art date
Application number
ARP180103000A
Other languages
Spanish (es)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR113771A1 publication Critical patent/AR113771A1/en

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente se refiere a moléculas de ácidos nucleicos que son complementarias a tanto la proteína 5 que contiene el dominio asociado a PAP (PAPD5) como la proteína 7 que contiene el dominio asociado a PAP (PAPD7), que conducen a la inhibición de la expresión de tanto PAPD5 como PAPD7 al utilizar una única molécula de ácidos nucleicos. Proporciona además moléculas de ácidos nucleicos específicas de PAPD5 y PAPD7 para la utilización en el tratamiento y/o prevención de una infección por el VHB, en particular una infección crónica por el VHB. Se encuentra comprendida además en la presente una composición farmacéutica para la utilización en el tratamiento y/o prevención de una infección por el VHB.This refers to nucleic acid molecules that are complementary to both protein 5 containing the PAP-associated domain (PAPD5) and protein 7 containing the PAP-associated domain (PAPD7), leading to inhibition of expression. of both PAPD5 and PAPD7 by using a single nucleic acid molecule. It further provides PAPD5 and PAPD7 specific nucleic acid molecules for use in the treatment and / or prevention of an HBV infection, in particular a chronic HBV infection. A pharmaceutical composition for use in the treatment and / or prevention of HBV infection is further encompassed herein.

ARP180103000A 2017-10-16 2018-10-16 NUCLEIC ACID MOLECULE FOR THE REDUCTION OF PAPD5 AND PAPD7 mRNA IN THE TREATMENT OF HEPATITIS B INFECTION AR113771A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17196554 2017-10-16

Publications (1)

Publication Number Publication Date
AR113771A1 true AR113771A1 (en) 2020-06-10

Family

ID=60117566

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180103000A AR113771A1 (en) 2017-10-16 2018-10-16 NUCLEIC ACID MOLECULE FOR THE REDUCTION OF PAPD5 AND PAPD7 mRNA IN THE TREATMENT OF HEPATITIS B INFECTION

Country Status (1)

Country Link
AR (1) AR113771A1 (en)

Similar Documents

Publication Publication Date Title
CL2020000945A1 (en) Nucleic acid molecule for the reduction of papd5 and papd7 mRNA in the treatment of hepatitis b infection.
PE20190443A1 (en) NUCLEIC ACID MOLECULES FOR THE REDUCTION OF PAPD5 OR PAPD7 mRNA TO TREAT HEPATITIS B INFECTION
CL2017002230A1 (en) Combined treatment with a tlr7 agonist and inhibitor of vhb capsid assembly.
AR112271A1 (en) COMPOSITIONS INCLUDING AN INHIBITOR OF RNA POLYMERASE AND CYCLODEXTRIN FOR THE TREATMENT OF VIRAL INFECTIONS
UY37581A (en) COMPOUNDS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION
BR112018009009A8 (en) combined therapy of an hbv capsid formation inhibitor and an interferon
UY37252A (en) COMPOUNDS FOR HEPATITIS B VIRUS INFECTION TREATMENT
CL2016000493A1 (en) Hcv polymerase inhibitors
CL2016001936A1 (en) Sulfamoylpirrolamide derivatives and their use as medicines for the treatment of hepatitis b
CL2020001146A1 (en) New indole-2-carboxamides substituted with pyrazolopiperidine, of high activity, active against the hepatitis b virus (HBV).
JOP20170161A1 (en) RNAi Agents for Hepatitis B Virus Infection
EA201792069A1 (en) DERIVATIVES OF AZOKANES AND AZONAS AND METHODS OF TREATING INFECTIONS OF HEPATITIS B
GT201500021A (en) SULFAMOILARILAMIDAS AND ITS USE AS MEDICINES FOR THE TREATMENT OF HEPATITIS B
BR112019004560A2 (en) combination treatment with tlr7 agonist and a hbv capsid formation inhibitor
CR20160520A (en) OLIGÓMEROS Y CONJUGADOS DE OLIGÓMEROS
CL2020001145A1 (en) New, high activity amino-thiazole substituted indole-2-carboxamides, active against hepatitis b virus (HBV).
UY33897A (en) HEPATITIS C VIRUS INHIBITORS
BR112018069974A2 (en) thiazolide compounds for the treatment of viral infections
BR112020020220A8 (en) use of fubp1 inhibitors to treat hepatitis b virus infection
DOP2016000336A (en) ISOINDOLIN DERIVATIVES FOR USE IN THE TREATMENT OF A VIRAL INFECTION
EA201790160A1 (en) METHODS OF TREATING INFECTIONS, CAUSED BY VIRUSES HEPATITIS B AND HEPATITIS D
AR114551A1 (en) COMPOSITIONS OF hdRNA AGENTS AGAINST HEPATITIS B VIRUS (HBV) AND METHODS FOR THEIR USE
CL2020001638A1 (en) Nucleic acid molecule for the reduction of papd5 and papd7 mRNA in the treatment of hepatitis b infection. (divisional request 202000945)
BR112019024549A2 (en) glycopeptide-derived compounds and uses thereof
PE20211306A1 (en) OLIGONUCLEOTIDES TO MODULATE THE EXPRESSION OF RTEL1